This administration resulted in a significant inhibition of Fibronectin protein expression and an increase in E-cadherin protein expression compared to the CML-treated group (Figure 6A-C). The gene discussed is FN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.